Labiotech.eu

News and Trends 18 Mar 2015

Novartis’ Jakavi receives European Commission approval

Novartis received the approval from the European Commission for Jakavi (ruxolitinib) for the treatment of adult patients with Polycythemia Vera (PV) who are resistant to or intolerant of hydroxyurea. Jakavi is the first targeted treatment approved by the European Commission for these patients. PV is a rare and incurable blood cancer associated with an overproduction […]

March 18, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 18 Mar 2015

Valneva penetrates Chinese Market thanks to a license agreement

A few months ago, the article “An Anglo-French Partnership To Cure Hepatitis B” related Valneva partnerships with Immune Targeting Systems. Today Valneva, a leading pure play vaccines biotech company is again on the front of the stage by announcing the exclusive license agreement with the Chinese company Jianshun Biosciences to commercialize Valneva’s EB66 cell line […]

March 18, 2015 - 2 minutesmins - By Joachim Eeckhout

Inside Labiotech 17 Mar 2015

Labiotech: Taking it to the next level

Today is an exciting day for us! In its short history, Labiotech has brought a fresh dynamic and original concepts to the Biotech media industry. So far, 5 Tours have been accomplished worldwide with 5 more to come still in 2015. For the first time, Labiotech has filmed entire biotech companies and ecosystems, to cover the latest […]

March 17, 2015 - 2 minutesmins - By Joachim Eeckhout

New oncology neoliquid neoplus cancer diagnosis

News and Trends 17 Mar 2015

New Oncology finances its Genetic Test for Cancer Diagnosis

New Oncology completed a financing round to prepare the market launch of NEOliquid, a non-invasive blood test that identifies therapeutically actionable genome alterations in the circulating free tumor DNA (ctDNA) of cancer patients. New Oncology’s pan-cancer diagnostic platform NEOplus reliably detects actionable genome alterations from one single patient sample with short turn-around times. In contrast to […]

March 17, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Mar 2015

MISSION Appoints Paul Wallace as Chief Business Officer

Mission Therapeutics, a company focused on the discovery and development of modulators of the deubiquitylating (DUB) enzyme family for the treatment of cancer and other diseases, appointed Paul Wallace as Chief Business Officer. The appointment highlights the scope and productivity of Mission’s drug discovery platform. Dr. Wallace joins Mission to formulate future business strategy at […]

March 16, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Mar 2015

Against Being Against GMOs: The Golden Rice Story

At the Zurich Life Science Day, I had the pleasure of hearing the keynote speaker, Professor Ingo Potrykus, Professor Emeritus of Plant Sciences at the Institute of Plant Sciences at ETH Zurich and creator of Golden Rice (GR). At 82 years old, he has the liveliness of someone much younger than him. While initially the […]

March 16, 2015 - 6 minutesmins - By Joachim Eeckhout

News and Trends 14 Mar 2015

Promising Collaboration Between Evotec and Second Genome

Evotec AG and Second Genome decided to collaborate in small molecule-based discovery and development activities for the treatment of microbiome-mediated diseases. The collaboration comprises the identification and optimisation of novel compounds as well as licence agreements for already existing assets developed by Evotec. Second Genome’s unique approach to identify and modulate microbiome-mediated pathways will be […]

March 14, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 14 Mar 2015

Samsung Bioepis Submits a Biosimilar Candidate, to the European Medicines Agency

Samsung Bioepis announced their submission to the to the European Medicines Agency (EMA) for SB2, its Remicade (Infliximab) biosimilar candidate. This is the second biosimilar candidate Marketing Authorization Application (MAA) that Samsung Bioepis has submitted to the EMA. The MAA is based on results from an extensive head-to-head preclinical data package comparing SB2 to the originator, a […]

March 14, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 13 Mar 2015

Get prepared: Pi day is coming!

Pi day, the unofficial annual holiday commemorating the math constant π, has this year a special significance. It is celebrated on March 14th, or 3/14 in the month/day date format, as the three first numbers of the constant. Furthermore, a sequential time will also happen tomorrow, on 3/14/15 at 9:26:53, when the clock will display […]

March 13, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 13 Mar 2015

Orgenesis acquires MaSTherCell

Orgenesis acquired MaSTherCell, an emerging pioneer in the industrialization of cell-based therapeutics based in Gosselies, Belgium, as part of the American company’s plan to increase its global presence and capabilities. The American and the Belgian companies have already been working jointly since last year to scale manufacturing of Orgenesis’ insulin-producing liver cells to fight diabetes. […]

March 13, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 12 Mar 2015

Alderley Park Life Science Campus, on the go

Manchester Science Partnerships (MSP) and Bruntwood have revealed plans for the first phase of development at their flagship 162-hectare life science campus at Alderley Park, Cheshire. The plans centered on the Mereside science campus and were revealed at MIPIM – the annual international property conference held in Cannes, France. The session, titled ‘Translating Science into […]

March 12, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 12 Mar 2015

Bioluminescent Bacteria and Algae, the Future Lighting

The University of Sevilla has patented a method for culturing the bacteria Vibrio fischeri and the algae Pyrocystus fusiformis in order to configure bioluminescent devices that emit light without electricity consumption, with applications in environmental lighting and signaling. Bioluminescence is a widespread phenomenon at all biological levels (bacteria, fungi, worms, insects, etc.). It consists of […]

March 12, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Novartis’ Jakavi receives European Commission approval

Valneva penetrates Chinese Market thanks to a license agreement

Labiotech: Taking it to the next level

New Oncology finances its Genetic Test for Cancer Diagnosis

MISSION Appoints Paul Wallace as Chief Business Officer

Against Being Against GMOs: The Golden Rice Story

Promising Collaboration Between Evotec and Second Genome

Samsung Bioepis Submits a Biosimilar Candidate, to the European Medicines Agency

Get prepared: Pi day is coming!

Orgenesis acquires MaSTherCell

Alderley Park Life Science Campus, on the go

Bioluminescent Bacteria and Algae, the Future Lighting

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!